Open access
Open access
Powered by Google Translator Translator

RCT | Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi.

15 Aug, 2022 | 11:55h | UTC

Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial – The Lancet Global Health

Commentaries:

Typhoid conjugate vaccine: are we heading towards the elimination of typhoid in endemic countries? – The Lancet Global Health

New TCV data from Malawi highlight longer-term immune response – Coalition Against Typhoid

Related:

Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children – New England Journal of Medicine

Cluster RCT: Vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh conferred 85% total protection.

Randomized Trial: Efficacy Analysis of a Typhoid Conjugate Vaccine

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.